Literature DB >> 1718129

Infratentorial ependymomas of childhood. Correlation between histological features, immunohistological phenotype, silver nucleolar organizer region staining values and post-operative survival in 16 cases.

D Figarella-Branger1, D Gambarelli, C Dollo, B Devictor, A M Perez-Castillo, L Genitori, G Lena, M Choux, J F Pellissier.   

Abstract

We have examined pathological criteria in 16 cases of infratentorial ependymomas of childhood using a conventional histological approach, with immunohistochemistry and silver nucleolar organizer region staining (AgNORs). We have found that some of these criteria are of prognostic value. The following histological features were evaluated in each case: cellular density, cellular or nuclear pleiomorphism, mitosis, focal necrosis, endothelial proliferation and complete loss of differentiation. The expression of the following antigens was also studied: epithelial membrane antigen (EMA), human natural killer (HNK1), glial fibrillary acidic protein (GFAP) and vimentin. Only three histological criteria have been retained as indicative of bad prognosis, i.e., high mitotic index, a large amount of necrosis and complete loss of differentiation. These criteria distinguish ependymomas from anaplastic ependymomas. GFAP was expressed in all tumors while other antigens were more variable. In addition tumors expressing large amounts of GFAP were statistically associated with a better prognosis. Increased vimentin expression associated with a decrease of GFAP immunoreactivity correlated with anaplasia and short survival. EMA was not directly correlated with postoperative survival but may be considered as a further prognostic factor. Finally AgNORs values were not statistically correlated with postoperative survival.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718129     DOI: 10.1007/bf00294447

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  38 in total

1.  Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level.

Authors:  D Ploton; M Menager; P Jeannesson; G Himber; F Pigeon; J J Adnet
Journal:  Histochem J       Date:  1986-01

Review 2.  Morphological markers in neuro-oncology.

Authors:  P Kleihues; M Kiessling; R C Janzer
Journal:  Curr Top Pathol       Date:  1987

3.  The effect of a series of fixatives on the AgNOR technique.

Authors:  P J Smith; N Skilbeck; A Harrison; J Crocker
Journal:  J Pathol       Date:  1988-06       Impact factor: 7.996

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Ependymomas: a clinicopathologic study.

Authors:  C E Rawlings; F Giangaspero; P C Burger; D E Bullard
Journal:  Surg Neurol       Date:  1988-04

6.  Ependymomas of childhood. I. Histological survey and clinicopathological correlation.

Authors:  H M Liu; J Boogs; J Kidd
Journal:  Childs Brain       Date:  1976

7.  Intracranial ependymomas in childhood. Survival and functional results of 47 cases.

Authors:  A Pierre-Kahn; J F Hirsch; F X Roux; D Renier; C Sainte-Rose
Journal:  Childs Brain       Date:  1983

8.  Supratentorial lobar ependymomas: reports on the grading and survival periods in 80 cases, including 46 recurrences.

Authors:  D Afra; W Müller; F Slowik; O Wilcke; H Budka; L Turoczy
Journal:  Acta Neurochir (Wien)       Date:  1983       Impact factor: 2.216

9.  Temporal relationship between the appearance of vimentin and neural tube development.

Authors:  J Houle; S Fedoroff
Journal:  Brain Res       Date:  1983-08       Impact factor: 3.252

10.  Glial fibrillary acidic protein (GFAP) in ependymal cells during development. An immunocytochemical study.

Authors:  U Roessmann; M E Velasco; S D Sindely; P Gambetti
Journal:  Brain Res       Date:  1980-10-27       Impact factor: 3.252

View more
  8 in total

Review 1.  Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis.

Authors:  Klara Kuncova; Ales Janda; Pavel Kasal; Josef Zamecnik
Journal:  Pathol Oncol Res       Date:  2009-03-20       Impact factor: 3.201

2.  A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma.

Authors:  D M Ho; C Y Hsu; T T Wong; H Chiang
Journal:  J Neurooncol       Date:  2001-08       Impact factor: 4.130

3.  Differential expression of cell adhesion molecules (CAM), neural CAM and epithelial cadherin in ependymomas and choroid plexus tumors.

Authors:  D Figarella-Branger; H Lepidi; C Poncet; D Gambarelli; N Bianco; G Rougon; J F Pellissier
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

4.  Immunohistochemical study of CD99 and EMA expression in ependymomas.

Authors:  Soheir Mahfouz; Ahmad Abdel Aziz; Samia M Gabal; Samar el-Sheikh
Journal:  Medscape J Med       Date:  2008-02-19

5.  Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005).

Authors:  Dayron Rodríguez; Michael C Cheung; Nadine Housri; Alfredo Quinones-Hinojosa; Kevin Camphausen; Leonidas G Koniaris
Journal:  J Surg Res       Date:  2009-05-14       Impact factor: 2.192

6.  Ependymomas: MIB-1 proliferation index and survival.

Authors:  A M Ritter; K R Hess; R E McLendon; L A Langford
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

7.  Immunohistochemical markers for prognosis of ependymal neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Valery Timirgaz
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

8.  Ependymoma in adults: surgery, reoperation and radiotherapy for survival.

Authors:  Dusan Vitanovics; Katalin Bálint; Zoltán Hanzély; Péter Banczerowski; Dénes Afra
Journal:  Pathol Oncol Res       Date:  2009-08-30       Impact factor: 3.201

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.